Nobivac Myxo RHD
A combined vaccine for rabbits
Nobivac Myxo-RHD, introduced in March of 2012, is the first vaccine to combine a full 12 months protection against both myxomatosis and rabbit haemorrhagic disease* (RHD), within a single inoculation.
So now you can give rabbits the protection they deserve more conveniently than ever before.
The new vaccine provides the following principal benefits:
- Single primary vaccination
- 12 months' duration of immunity against both diseases
- Subcutaneous injection: no need for intradermal vaccination
- Onset of immunity within 3 weeks
- Can be given from 5 weeks of age onwards
- Improved immunity against myxomatosis
- Available in single dose vials (with peel-off labels)
The opportunity for greater protection
Our third most popular mammalian pet, the estimated UK domestic rabbit population is around 0.8 million pet rabbits (PFMA, 2016). Unfortunately, estimates based on vaccine sales suggest that fewer than 26 % are vaccinated, and yet the frequency of myxomatosis alone suggests that vaccine-preventable fatal infectious disease appears to be more widely seen in rabbits than any other pet species.
Cases of rabbit haemorrhagic disease (RHD) are sporadic and may be hard to confirm without post-mortem, but this too is endemic and presents a significant threat to unvaccinated rabbits. Rabbit owners can be highly motivated to provide proper care for their pets, but many simply don't understand the disease threat faced by their animals.
There is an emerging strain of Rabbit Viral Haemorrhagic Disease (RHDV2) that was first noted in France in 2010, with cases noted in the UK from 2013. Clinical signs and mortality rates are variable and affected rabbits can show signs from sudden death, to slow recovery, and also include some rabbits that do not show any clinical signs. This emerging variant strains are being reported sporadically but widely and at the time of writing it is difficult to quantify the risk of vriant strain RHD to UK rabbits. The disease caused by variant RHDV differs from that caused by classical strain virus, in that it may take longer for the clinical signs to develop. Unlike the original strain this strain can affect young rabbits, including those under 4 weeks of age. This strain can also affect hares. At the time of writing Nobivac Myxo-RHD is licensed to prevent mortality due to classic strains of RHD. Any ability to cross protect against emerging strains of RHD has not been established.
Some European RHD vaccines for rabbits, unlicensed for use in the United Kingdom, have obtained a claim for a level of protection against variant RHD, however special import is required and supplies are limited. Some veterinary surgeons are recommending the additional use of imported RHD vaccine to broaden the cover in UK rabbits against Rabbit Haemorrhagic Disease. It of course remains vitally important that all rabbits continue to receive protection against both myxomatosis and classic strain RHD, and that as far as is practical, steps are taken as far as possible to minimise direct or indirect contact between pet rabbits and their wild cousins, as well as to reduce the opportunity for spread of infectious diseases via insect vectors such as fleas, mites and flies.